Evaluating the effect of Spirulina in Non-alcoholic ?fatty liver patient.

Not Applicable

• Conditions: Fatty (change of) liver, not elsewhere classified; on-alcoholic fatty liver.; K76.0

• Registration Number: IRCT20200304046692N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Individuals with Non-alcoholic fatty liver disease

Exclusion Criteria

Individuals with malnutrition
Individuals with alcohol consumption
taking lipid-lowering drugs
following special diets such as vegetarian or raw vegetarian
diseases such as diabetes mellitus, cardiovascular disease, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction, hepatic injury induced by hereditary hemochromatosis drugs, sclerosis cholangitis, and a antisense deficiency), cancer, renal failure, celiac; being in pregnancy and lactation.
taking Drugs that cause fatty liver (methotrexate, tamoxifen, valproate, etc.)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The degree of fatty liver. Timepoint: Before and after 8 weeks of intervention. Method of measurement: liver ultrasound.

Secondary Outcome Measures

Name	Time	Method
Anthropometric indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Digital scales and tape meters.;Lipid profile. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Systolic and diastolic blood pressure. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Mercury barometer.;Blood sugar indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.;Inflammatory indices. Timepoint: Before and after 8 weeks of intervention. Method of measurement: enzyme-linked immunosorbent assay( ELISA)kit.;Liver enzymes. Timepoint: Before and after 8 weeks of intervention. Method of measurement: Kit.